KT-502

N/A

Report date: 2026/05/06 20:02:28

Base Information

Drug NameKT-502

Drug Alias NameKT-502

ClassificationBiologics > T cell engagersBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionCD3 T-cell engagersAnti-CD19

TargetsT cell surface glycoprotein CD3B-lymphocyte antigen CD19

Therapy Area/IndicationsAutoimmune DiseasesArthritis, Rheumatoid

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesNew ZealandAustralia

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesKali Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesKali Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsAutoimmune DiseasesArthritis, Rheumatoid

Inactive IndicationsN/A

Other Information

ATC CodeN/A